Company
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 19 of 55
"This is the first time a dual immunotherapy regimen has improved overall survival as a 1st-line treatment for patients with unresectable liver cancer for whom treatment options are limited and long-term outcomes are poor," said Susan Galbr
Merck and AstraZeneca have developed medicines that can prevent people infected with the virus from developing serious symptoms
The median price target for AZ shares is £99.91, suggesting upside of 11.5% from current levels. Investment bank Berenberg reckons the stock is worth £105
AZD7442 is the first LAAB with Phase III data to demonstrate benefit in both prophylaxis and treatment of COVID-19, said the pharma giant
Phase III trial results showed showed a 77% reduction in risk of developing symptomatic COVID-19 with the long-acting antibody combination AZD7442
Caleum is investigating a drug to treat light chain amyloidosis, a fatal, rare disease in which abnormal proteins build up in organs throughout the body
While chief executive Pascal Soriot has said he had no regrets over getting involved in vaccines, there is a growing recognition among execs that a rethink may be in order
The pharma giant has racked in successes in its oncology pipeline and it's also entering the rare disease world with Alexion: is it time to move on?
Lynparza used with the current standard of care showed better results than the standard of care alone
Revenue was lifted by the COVID-19 vaccine agreement with AstraZeneca
The new facility is expected to create about 100 highly skilled direct jobs, including scientists and engineers, and further indirect jobs
Two leading banks reckon the the stock could kick on after Monday's move higher
"Immunity is lasting well in the majority of people," Prof Dame Sarah Gilbert told the Telegraph
"It will now be for the (JCVI) to advise on whether booster jabs will be given."
The drug met all primary goals in two late-stage studies involving over 4,000 people
“A third dose for all may be needed, but it may not"
Under the settlement announced by the European Commission, AstraZeneca will deliver 200 million doses by the end of March 2022
Under the settlement announced by the European Commission, AstraZeneca will deliver 200 million doses by the end of March 2022
The anti-cancer vaccine was designed to target two MAGE-type proteins found on many cancer cells
The research team studied records of more than 29mln people who received the first dose of a COVID-19 vaccine between Dec and Apr, and the records of almost 1.8mln people who had been infected with the virus
